CHRS

CHARMING SHOPPES INC

CHRS

Overview Fund Activity

Delisted

CHRS was delisted on the 14th of June, 2012.

Back to rankings

Consumer Discretionary Apparel Retail

Financial journalist opinion

Coherus Oncology: On The Shaping Up

Coherus Oncology remains a speculative play, with a strong cash position post-Udenyca sale and a cash runway into 2026 supporting ongoing pipeline development. Toripalimab sales are steady but limited by a small patient population, so financial viability hinges on the success of novel pipeline agents like casdozokitug and CHS-114. Pipeline risks are significant, as neither IL-27 nor CCR8 targeting has shown efficacy in cancer yet, and early-stage biotech projects face high attrition rates.

Coherus Oncology: On The Shaping Up

Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript

Coherus Oncology, Inc. (NASDAQ:CHRS ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Bryan J. McMichael - Chief Financial Officer Dennis M.

Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript

The Motley Fool

Coherus (CHRS) Q2 Revenue Jumps 10%

Coherus (CHRS) Q2 Revenue Jumps 10%

Coherus (CHRS) Q2 Revenue Jumps 10%

Zacks Investment Research

Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates

Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.14 per share a year ago.

Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif.

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Jodi Sievers - Head, Investor Relations Denny Lanfear - Chief Executive Officer Theresa LaVallee - Chief Scientific & Development Officer Rosh Dias - Chief Medical Officer Sameer Goregaoker - Executive Vice President, Commercial Bryan McMichael - Chief Financial Officer Conference Call Participants Kripa Devarakonda - Truist Securities Brian Cheng - JPMorgan Mike Nedelcovych - TD Cowen Colleen Kusy - Baird Douglas Tsao - H.C. Wainwright Operator Good day and thank you for standing by.

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago.

Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million and UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif.

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

See News Rankings

Charts implemented using Lightweight Charts™